letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...3132333435363738394041...100101»
  • ||||||||||  Clinical, Review, Journal:  Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer. (Pubmed Central) -  May 19, 2022   
    In the past decade, the introduction of molecularly targeted agents against intracellular targets such as mammalian target of rapamycin (everolimus), cyclin-dependent kinases 4 and 6 (palbociclib, ribociclib, and abemaciclib), and phosphatidylinositol 3-kinase (alpelisib) has offered patients effective nonchemotherapy-based options, which are improving outcomes...Still, formatting a plan for these patients includes taking into account traditional prognostic factors such as menopausal status, previous treatments, disease-free interval for those patients with early breast cancer that has recurred, and tumor burden. To assist in developing this treatment plan, we will review the current data with systemic agents in the management of these patients.
  • ||||||||||  letrozole / Generic mfg., vardenafil / Generic mfg.
    Preclinical, Journal:  Testosterone positively regulates vagina NO-induced relaxation: an experimental study in rats. (Pubmed Central) -  May 19, 2022   
    To assist in developing this treatment plan, we will review the current data with systemic agents in the management of these patients. Our study demonstrates that testosterone improves the NO-mediated smooth muscle vaginal cells relaxation confirming its role in maintaining the integrity of muscular relaxant machinery.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Myo-Inositol for Infertility in PCOS (clinicaltrials.gov) -  May 18, 2022   
    P=N/A,  N=168, Recruiting, 
    Trial completion date: Aug 2022 --> Aug 2026 Trial completion date: Jan 2022 --> Sep 2023 | Trial primary completion date: Jan 2022 --> Sep 2023
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    EFFICACY OF LIMITED DOSE MODIFICATIONS FOR PALBOCICLIB-RELATED GRADE 3 NEUTROPENIA IN HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER () -  May 16, 2022 - Abstract #GBCC2022GBCC_370;    
    HR-positive, human epidermal growth factor receptor 2-negative mBC patients (434) who received palbociclib with letrozole as first-line therapy were analyzed and classified into four groups based on neutropenia grade and afebrile grade 3 neutropenia management: Group 1 (maintained palbociclib dose, limited scheme), Group 2 (dose delay or reduction, conventional scheme), Group 3 (no afebrile grade 3 neutropenia event), and Group 4 (grade 4 neutropenia event). Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS than the conventional dose scheme without increasing toxicities.
  • ||||||||||  LOXO-783 / Eli Lilly
    Enrollment open, Combination therapy, Monotherapy, Metastases:  PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) -  May 15, 2022   
    P1,  N=260, Recruiting, 
    Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS than the conventional dose scheme without increasing toxicities. Not yet recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Review, Journal:  Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review. (Pubmed Central) -  May 12, 2022   
    Our case and the literature show that single-agent letrozole is capable to treat deep infiltrative endometriosis involving the rectum and the urinary tract...Multidisciplinary involvement of the gynecologist, bowel surgeon, urologist and invasive radiologist might be needed. Aromatase inhibitors should be considered to be an integral part of the armamentarium in the management of women with endometriosis, especially in refractory cases that have failed conventional therapeutic modalities.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study of Abemaciclib in Indian Women With Advanced Breast Cancer (clinicaltrials.gov) -  May 11, 2022   
    P4,  N=200, Recruiting, 
    NAC can control and treat pathological parameters and help as a harmless drug in the treatment of women with PCOS. Trial completion date: Aug 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Journal:  Population-wide contribution of medically assisted reproductive technologies to overall births in Australia: temporal trends and parental characteristics. (Pubmed Central) -  May 10, 2022   
    With the ubiquitous decline in fertility rates around the world and the increasing trend to delay childbearing, this population-based study enhances our understanding of the contribution of different types of MARs to population profiles among births in high-income countries. The parental socio-demographic characteristics of MAR-conceived children differ significantly from naturally conceived children and this highlights the importance of accounting for such differences in studies investigating the health and development of MAR-conceived children.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Estrogen Promotes Microvascularization in the Fetus and thus Vascular Function and Insulin Sensitivity in Offspring. (Pubmed Central) -  May 10, 2022   
    Along with vascular dysfunction, peak insulin and glucose levels during a glucose tolerance test were greater (P<0.05 ̶ P<0.01) and the homeostasis model of insulin resistance 2-fold higher (P<0.01) in offspring of letrozole-treated than untreated animals, indicative of insulin resistance. This study makes the novel discovery that estrogen promotes microvascularization in the fetus and thus normal vascular development and function required for eliciting insulin sensitivity in offspring, and that placental hormonal secretions, independent from improper fetal growth, are an important determinant of risk of developing insulin resistance.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients (clinicaltrials.gov) -  May 10, 2022   
    P1/2,  N=95, Recruiting, 
    This study makes the novel discovery that estrogen promotes microvascularization in the fetus and thus normal vascular development and function required for eliciting insulin sensitivity in offspring, and that placental hormonal secretions, independent from improper fetal growth, are an important determinant of risk of developing insulin resistance. Trial completion date: Dec 2021 --> Oct 2023 | Trial primary completion date: Jun 2021 --> Oct 2023
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) -  May 9, 2022   
    P3,  N=80, Recruiting, 
    Trial completion date: Dec 2021 --> Oct 2023 | Trial primary completion date: Jun 2021 --> Oct 2023 Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome (clinicaltrials.gov) -  May 9, 2022   
    P3,  N=150, Recruiting, 
    Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Nov 2021 --> Aug 2023 | Trial primary completion date: Sep 2021 --> Dec 2022
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  A new Cu(II)-containing coordination polymer: protective effect and mechanism exploration on elderly osteoporotic hip fractures via regulating the wnt signaling pathway. (Pubmed Central) -  May 6, 2022   
    The reaction between Cu(II) salt and 4,4'-(1H-1,2,4-triazol-1-yl)methylene-bis(benzoic acid) (Htzmb), an aromatase inhibitor letrozole derivative with the aid of the organic linker 4,4-bipyridine (4,4'-bpy) affords a new coordination polymer based on Cu(II) ions as nodes of {[Cu(tzmb)(4,4'-bpy) (μ-HO)(DMA) (HO)]·10DMA} (1)...The molecular docking simulation results have identified that only the carboxyl group on the Cu complex exhibits the activity for the hydrogen bond formation, however, the pyridine ring does not have such activity, instead, the pyridine ring only acts as the ligand that binds to the Cu ion. This Cu(II) coordination polymer has excellent application values on the elderly osteoporotic hip fractures treatment by increasing the activation of wnt signaling pathway in mesenchymal stem cell.
  • ||||||||||  letrozole / Generic mfg.
    Retrospective data, Review, Journal:  Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis. (Pubmed Central) -  May 6, 2022   
    The quality of evidence was high or moderate in the RCTs and low in the observational studies. In conclusion, poor responders may benefit from co-treatment with letrozole during ovarian stimulation for IVF, whereas letrozole for normal and high responders requires further investigation with larger, high-quality studies.
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    SESSION I: Immunopathology and treatment of PCOS (VIRTUAL) -  May 6, 2022 - Abstract #ASRI2022ASRI_4;    
    In addition, the antiinflammatory effect of vitamin D has also been reported to be effective. Although the pathogenesis of PCOS remains unclear, further research into immunological pathogenesis will help to discover new therapeutic Strategies.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Trial completion date, Trial primary completion date:  TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) -  May 3, 2022   
    P3,  N=144, Recruiting, 
    The role of phenotypic sub-categorisation for variable response to letrozole as an ovulation-inducing agent is uncertain. Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
  • ||||||||||  tagtociclib (PF-07104091) / Pfizer
    Phase classification, Trial completion date, Trial primary completion date, Combination therapy:  PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) -  May 2, 2022   
    P2,  N=240, Recruiting, 
    Trial completion date: Mar 2022 --> Mar 2025 | Trial primary completion date: Mar 2022 --> Mar 2024 Phase classification: P1/2 --> P2 | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
  • ||||||||||  diacerein / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal:  Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats. (Pubmed Central) -  Apr 28, 2022   
    Finally, DIA inhibited the elevated mRNA levels of NLRP3 and caspase-1, the up-regulated inflammatory cytokines IL-6, TNF-α, and the IL-1β/NFκB signaling pathway. Our results proved that DIA ameliorates letrozole-induced PCOS through its antioxidant and anti-inflammatory properties.